The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
Official Title: A Randomized, Open, Multicenter Phase 1/Phase 2 Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
Study ID: NCT05783921
Brief Summary: To evaluate the efficacy and safety of TQB2618 injection combined with Penpulimab and chemotherapy in the first-line treatment of relapsed/metastatic head and neck squamous cell carcinoma compared to Penpulimab combined chemotherapy. Progression-free survival (PFS) and objective response rate (ORR) were the primary efficacy endpoints.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Gansu Prouincial Cancer Hospital, Lanzhou, Gansu, China
Jiangmen Central Hospital, Jiangmen, Guangdong, China
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
AnYang Tumor Hospital, Anyang, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Zhumadian Centre Hospital, Zhumadian, Henan, China
Hunan Cancer Hospital, Changsha, Hunan, China
Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
Liaoning Cancer hospital, Shenyang, Liaoning, China
The Second Hospital Of Dalian Medical University, Shenyang, Liaoning, China